Newsroom | 9961 results

MILÁN--(BUSINESS WIRE)--Corcym, una empresa de dispositivos médicos global dedicada a la cirugía cardiaca, anunció hoy que se incluyeron datos positivos a mediano plazo de un subanálisis de su válvula cardíaca aórtica sin sutura Perceval Plus como parte de su ensayo clínico MANTRA en una presentación oral realizada hoy en la reunión anual de la European Association for Cardio-Thoracic Surgery (EACTS). El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducc...

MILAAN--(BUSINESS WIRE)--Corcym, een wereldwijd bedrijf in medische hulpmiddelen dat zich richt op hartchirurgie, heeft vandaag bekendgemaakt dat positieve gegevens op middellange termijn, afkomstig uit een subanalyse van de klinische MANTRA-studie naar de hechtingloze aortaklep Perceval Plus, zijn gepresenteerd tijdens de jaarvergadering van de European Association for Cardio-Thoracic Surgery (EACTS). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als...

MILANO--(BUSINESS WIRE)--Corcym, lo specialista globale dei dispositivi medici cardiochirurgici, oggi ha annunciato la presentazione dei dati positivi a medio termine di una sottoanalisi della sua valvola aortica senza suture Perceval Plus, parte dello studio clinico MANTRA, nel corso della presentazione orale odierna al congresso annuale della European Association for Cardio-Thoracic Surgery (EACTS). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione uffi...

MILAN--(BUSINESS WIRE)--Corcym, une société d’envergure mondiale spécialisée dans les dispositifs médicaux destinés à la chirurgie cardiaque, a annoncé aujourd’hui que les résultats positifs à moyen terme issus d’une sous-analyse de sa valve aortique sans suture Perceval Plus, réalisée dans le cadre de son essai clinique MANTRA, avaient fait aujourd’hui l’objet d’une présentation orale à l’occasion du congrès annuel de l’European Association for Cardio-Thoracic Surgery (EACTS). Cette étude, qui...

MAILAND--(BUSINESS WIRE)--Corcym, ein weltweit tätiges Medizintechnikunternehmen mit Schwerpunkt auf Herzchirurgie, gab heute bekannt, dass positive Zwischenergebnisse aus einer Subanalyse seiner nahtlosen Aortenherzklappe „Perceval Plus“ im Rahmen der klinischen Studie „MANTRA“ heute in einem Vortrag auf der Jahrestagung der European Association for Cardio-Thoracic Surgery (EACTS) vorgestellt wurden. Die Studie ist die längste verfügbare Nachbeobachtungsstudie zu Perceval Plus und der FREE-Gew...

MILAN--(BUSINESS WIRE)--Corcym's Perceval Plus sutureless aortic heart valve shows excellent durability, safety and quality of life at up to 7 years at EACTS meeting....

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and translational data and the Phase 1/2 UPBEAT™ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), will be featured at the Heart Failure So...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced that clinical data from its Phase 1 study evaluating STM-01 in patients with heart failure with preserved ejection fraction (HFpEF) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting.STM-01 is an investigational biologic therapy derived from neonatal cardiac progenito...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o...

MENLO PARK, Calif.--(BUSINESS WIRE)--Hello Heart, the leader in AI-powered preventive heart health, today announced that Charles “Chuck” MacGlashing has joined the company as Chief Financial Officer as Hello Heart enters its next stage of growth. MacGlashing joins Hello Heart after more than a decade at HubSpot, where he most recently served as Senior Vice President of Treasury, Corporate Development, and Investor Relations. In that role, he was a key voice for HubSpot with investors and Wall S...